Breaking News

Navin Molecular Expands GMP Manufacturing Capabilities

Will invest up to $35 million to construct a 9,000 square meter GMP manufacturing plant in Dewas, India.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Navin Molecular, an Indian-headquartered contract development and manufacturing organization (CDMO) with small molecule development and manufacturing capabilities, announced a Rs 288 Crore (approximately US$35 million) investment to construct a 9,000 square meter GMP manufacturing plant in Dewas, India. The new facility will nearly double overall capacity at the site to 420 cubic meters, and will support existing commercial-scale projects, as well as meeting future demands as the company continu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters